Regenacy Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Regenacy Pharmaceuticals they give services to treat diabetic and other peripheral neuropathies.
Regenacy Pharmaceuticals has raised $47.1M across 3 funding rounds on record, the most recent a Series B of $9.3M announced in Aug 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Regenacy Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Aug 2022.
Regenacy Pharmaceuticals Funding Rounds
Regenacy Pharmaceuticals raised $30.0M in an undisclosed round announced in Mar 2020.
1.9 years later, a Series B of $7.8M was announced in Feb 2022.
6 months later, a Series B of $9.3M was announced in Aug 2022.
Regenacy Pharmaceuticals Founders and Leadership Team
Contact details for the Regenacy Pharmaceuticals team: 2 of 3 have an email address on file.
Start 14-day free trial →Regenacy Pharmaceuticals Funding Compared to Other Biotechnology Startups
Regenacy Pharmaceuticals' latest round of $9.3M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Regenacy Pharmaceuticals in Biotechnology and Waltham
Companies Similar to Regenacy Pharmaceuticals
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Regenacy Pharmaceuticals Funding FAQs
What does Regenacy Pharmaceuticals do?
Regenacy Pharmaceuticals they give services to treat diabetic and other peripheral neuropathies.
How much funding has Regenacy Pharmaceuticals raised?
Regenacy Pharmaceuticals has raised $47.1M across 3 rounds on record. The most recent is a Series B of $9.3M announced in Aug 2022.
When did Regenacy Pharmaceuticals last raise funding?
Regenacy Pharmaceuticals' most recent funding round on record is a Series B of $9.3M, announced in Aug 2022.
Who is the CEO of Regenacy Pharmaceuticals?
Simon Jones is listed as CEO at Regenacy Pharmaceuticals.
Where is Regenacy Pharmaceuticals headquartered?
Regenacy Pharmaceuticals is based in Waltham, Massachusetts, United States.
How many employees does Regenacy Pharmaceuticals have?
Regenacy Pharmaceuticals is in the 11-50 employee band.
How does Regenacy Pharmaceuticals' funding compare to other Biotechnology startups?
Regenacy Pharmaceuticals' latest round of $9.3M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Regenacy Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Regenacy Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.